Intra-Cellular Therapies (NASDAQ:ITCI) Posts Earnings Results, Misses Expectations By $0.08 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08), Zacks reports. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI traded up $0.09 during midday trading on Friday, hitting $128.63. The company’s stock had a trading volume of 544,565 shares, compared to its average volume of 4,170,858. Intra-Cellular Therapies has a 12-month low of $62.78 and a 12-month high of $128.77. The company has a market cap of $13.68 billion, a P/E ratio of -147.86 and a beta of 0.72. The business’s 50 day simple moving average is $109.36 and its 200 day simple moving average is $89.29.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. JPMorgan Chase & Co. increased their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.